Organon Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Organon wird ein jährliches Gewinn- und Umsatzwachstum von 4.1% bzw. 0.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 3.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 106% betragen.

Wichtige Informationen

4.1%

Wachstumsrate der Gewinne

3.5%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	0.2%
Zukünftige Eigenkapitalrendite	106.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	19 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year

May 29

High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued

Dec 19

Organon: It's Darkest Before The Dawn

Nov 30

Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace

Nov 07

Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28

Nov 05

Organon: The Federal Reserve Black Swan (Rating Upgrade)

Oct 04

6% Yield And Significantly Undervalued: A Closer Look At Organon

Sep 10

Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk

Aug 10

Organon & Co.: A Tough Spot To Be In Right Now

Jul 16

Organon goes ex-dividend tomorrow

Feb 23

Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 19

Is There Anything Organic Or Interesting About Organon?

Feb 07

Organon goes ex-dividend tomorrow

Nov 09

Organon's (NYSE:OGN) Dividend Will Be $0.28

Nov 08

Take Care Before Diving Into The Deep End On Organon & Co. (NYSE:OGN)

Nov 05

Organon: Thoughts Ahead Of Q3 Earnings

Oct 31

Organon: What Is The Recipe?

Aug 31

Oragenics announces early toxicology data for intranasal COVID-19 vaccine

Aug 24

Organon, Samsung Bioepis Humira biosimilar Hadlima high concentration dosage gets FDA nod

Aug 17

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Aug 07

Organon Q2 2022 Earnings Preview

Aug 03

Organon in pact with Cirqle Biomedical for contraceptive candidate

Jul 28

Organon: Some Uncomfortable Questions Ahead Of Q2 Earnings

Jul 18

Organon Vs. Viatris: Who Is The Clear Winner?

Jun 20

Organon: Maximum Optimism

Apr 28

Gewinn- und Umsatzwachstumsprognosen

NYSE:OGN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	6,542	1,071	1,121	1,177	6
12/31/2025	6,467	971	1,050	1,128	7
12/31/2024	6,391	751	797	1,369	7
3/31/2024	6,347	1,047	458	761	N/A
12/31/2023	6,263	1,023	538	799	N/A
9/30/2023	6,150	585	424	669	N/A
6/30/2023	6,168	754	320	725	N/A
3/31/2023	6,145	746	431	849	N/A
12/31/2022	6,174	917	431	858	N/A
9/30/2022	6,292	1,011	138	638	N/A
6/30/2022	6,355	1,107	343	689	N/A
3/31/2022	6,365	1,304	564	1,077	N/A
12/31/2021	6,304	1,351	1,970	2,458	N/A
9/30/2021	6,314	1,525	2,370	2,841	N/A
6/30/2021	6,327	1,762	2,304	2,761	N/A
3/31/2021	6,258	1,917	2,772	3,025	N/A
12/31/2020	6,532	2,256	1,932	2,187	N/A
12/31/2019	7,777	3,306	2,675	2,767	N/A
12/31/2018	9,777	2,153	3,586	3,687	N/A
12/31/2017	10,500	1,801	N/A	3,419	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: OGNDas prognostizierte Gewinnwachstum (4.1% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: OGNDie Erträge des Unternehmens (4.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: OGNDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: OGNDie Einnahmen des Unternehmens (0.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: OGNDie Einnahmen des Unternehmens (0.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: OGNDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (106%).

Organon Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Organon & Co. Provides Earnings Guidance for the Year 2023

Consensus EPS estimates fall by 22%

Price target decreased by 13% to US$24.56

Organon & Co. Revises Earnings Guidance for the Full Year 2023

Price target decreased by 7.8% to US$28.38

Consensus EPS estimates fall by 16%

Recent updates

Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals

Four Reasons Why Organon Stock Is A Good Buy

First quarter dividend of US$0.28 announced

First quarter 2024 earnings released: EPS: US$0.79 (vs US$0.70 in 1Q 2023)

Organon & Co. Provides Earnings Guidance for the Year 2023

Organon & Co., Annual General Meeting, Jun 04, 2024

Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings

Organon & Co. to Report Q1, 2024 Results on May 02, 2024

CEO & Director exercised options and sold US$628k worth of stock

CEO & Director exercised options and sold US$729k worth of stock

Organon Stock Is Still Worth A Look

US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Fourth quarter dividend of US$0.28 announced

Full year 2023 earnings: EPS exceeds analyst expectations

Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last

Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024

Organon & Co. to Report Q4, 2023 Results on Feb 15, 2024

Investor sentiment improves as stock rises 18%

Organon’S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older

Organon: What I'm Looking For In This 8% Yield In 2024

High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued

Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024

Organon: It's Darkest Before The Dawn

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 22%

Samsung Bioepis & Organon Announces FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (Adalimumab-bwwd)

Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace

Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28

Price target decreased by 13% to US$24.56

Organon & Co. Declares a Quarterly Dividend, Payable on December 14, 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Organon & Co. to Report Q3, 2023 Results on Nov 02, 2023

Organon: The Federal Reserve Black Swan (Rating Upgrade)

Organon & Co.(NYSE:OGN) dropped from FTSE All-World Index (USD)

Organon Announces First Real-World Observational Study of the JADA® System

6% Yield And Significantly Undervalued: A Closer Look At Organon

Organon Announces Two Leadership Appointments

Organon & Co. Revises Earnings Guidance for the Full Year 2023

Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Samsung Bioepis & Organon Announces Topline Results from Interchangeability Study of SB5 Humira Biosimilar

Price target decreased by 7.8% to US$28.38

Organon & Co. to Report Q2, 2023 Results on Aug 08, 2023

Organon & Co.: A Tough Spot To Be In Right Now

Organon & Co. & Samsungbioepis Co,.Ltd Announces US Launch of Humira Biosimilar Hadlima (adalimumab-Bwwd) in Multiple Presentations Consistent with Originator

Consensus EPS estimates fall by 16%

Organon & Co. Declares Guidance Quarterly Dividend, Payable on June 15, 2023

First quarter 2023 earnings: EPS misses analyst expectations

CEO & Director exercised options and sold US$275k worth of stock

CEO & Director exercised options and sold US$160k worth of stock

Organon goes ex-dividend tomorrow

Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Full year 2022 earnings: EPS misses analyst expectations

Organon Declares Quarterly Dividend, Payable on March 16, 2023

Organon & Co. to Report Q4, 2022 Results on Feb 16, 2023

Is There Anything Organic Or Interesting About Organon?

Organon & Co. Appoints Kirke Weaver as General Counsel and Corporate Secretary, Effective January 1, 2023

Organon Canada Launches Ontruzant®, A Biosimilar of the Reference Biologic Herceptin®, Providing Patients in Canada with Certain Breast and Gastric Cancers with an Additional Therapeutic Option At A Lower Cost

Organon goes ex-dividend tomorrow

Organon's (NYSE:OGN) Dividend Will Be $0.28

Organon Canada Launches Aybintio Providing New Option at Reduced Cost for Canadians Living with Certain Aggressive Forms of Cancer

Take Care Before Diving Into The Deep End On Organon & Co. (NYSE:OGN)

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Organon & Co. Revises Earnings Guidance for the Full Year 2022

Organon: Thoughts Ahead Of Q3 Earnings

Price target decreased to US$34.50